Document is current
Any future updates will be listed below
-
Authors
Coates, Laura C https://orcid.org/0000-0002-4756-663X
Landewé, Robert https://orcid.org/0000-0002-0577-6620
McInnes, Iain B https://orcid.org/0000-0002-6462-4280
Mease, Philip J https://orcid.org/0000-0002-6620-0457
Ritchlin, Christopher T https://orcid.org/0000-0002-2602-1219
Tanaka, Yoshiya https://orcid.org/0000-0002-0807-7139
Asahina, Akihiko
Behrens, Frank https://orcid.org/0000-0001-8750-7186
Gladman, Dafna D https://orcid.org/0000-0002-9074-0592
Gossec, Laure https://orcid.org/0000-0002-4528-310X
Orbai, Ana-Maria https://orcid.org/0000-0001-8644-8567
Gottlieb, Alice B
Warren, Richard B
Ink, Barbara
Bajracharya, Rajan
Shende, Vishvesh
Coarse, Jason
Merola, Joseph F
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03896581 at ClinicalTrials.govnct04009499 at ClinicalTrials.govDocuments that mention this clinical trial
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2025-006174
Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 Year
https://doi.org/10.1007/s13555-025-01599-5
POS0969 BIMEKIZUMAB-TREATED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS SHOWED SUSTAINED ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AND REMISSION: UP TO 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.2557
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s40744-024-00652-7
Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis
https://doi.org/10.1136/rmdopen-2023-003548
AB1099 SUSTAINED EFFICACY OF BIMEKIZUMAB TREATMENT ASSESSED USING COMPOSITE DISEASE ACTIVITY MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN LABEL EXTENSION UP TO 1 YEAR
https://doi.org/10.1136/annrheumdis-2023-eular.1671
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2024-005026
Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes
https://doi.org/10.1136/rmdopen-2021-002074
POS0590-HPR IDENTIFICATION OF RESPONDER AND DISEASE ACTIVITY THRESHOLDS FOR THE PSORIATIC ARTHRITIS IMPACT OF DISEASE-12 (PSAID-12) QUESTIONNAIRE USING POOLED DATA FROM TWO PHASE 3 TRIALS OF BIMEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.1980
POS1533 BIMEKIZUMAB TREATMENT RESULTED IN CLINICALLY MEANINGFUL IMPROVEMENTS IN THE PSORIATIC ARTHRITIS IMPACT OF DISEASE-12 (PSAID-12) SCORES USING POOLED RESULTS FROM TWO PHASE 3 TRIALS IN PATIENTS WITH PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.1305
POS0231 SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION UP TO 1 YEAR
https://doi.org/10.1136/annrheumdis-2023-eular.1306
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s40744-024-00706-w
Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies
https://doi.org/10.1136/rmdopen-2024-004464
OP0255 BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: 16-WEEK EFFICACY & SAFETY FROM BE COMPLETE, A PHASE 3, MULTICENTRE, RANDOMISED PLACEBO-CONTROLLED STUDY
https://doi.org/10.1136/annrheumdis-2022-eular.2265
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
https://doi.org/10.1136/rmdopen-2023-003855
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies
https://doi.org/10.1007/s40744-024-00708-8
POS0961 BIMEKIZUMAB MAINTAINED EFFICACY RESPONSES THROUGH 52 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.1239
Documents that mention this clinical trial
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2025-006174
Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 Year
https://doi.org/10.1007/s13555-025-01599-5
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study
https://doi.org/10.1136/ard-2023-224431
POS0969 BIMEKIZUMAB-TREATED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS SHOWED SUSTAINED ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AND REMISSION: UP TO 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.2557
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s40744-024-00652-7
AB1099 SUSTAINED EFFICACY OF BIMEKIZUMAB TREATMENT ASSESSED USING COMPOSITE DISEASE ACTIVITY MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN LABEL EXTENSION UP TO 1 YEAR
https://doi.org/10.1136/annrheumdis-2023-eular.1671
Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies
https://doi.org/10.1136/rmdopen-2024-005026
POS0231 SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION UP TO 1 YEAR
https://doi.org/10.1136/annrheumdis-2023-eular.1306
Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies
https://doi.org/10.1136/rmdopen-2024-004464
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
https://doi.org/10.1136/rmdopen-2023-003855
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies
https://doi.org/10.1007/s40744-024-00708-8
POS0961 BIMEKIZUMAB MAINTAINED EFFICACY RESPONSES THROUGH 52 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM TWO PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2024-eular.1239
-
Funding
Funding for this research was provided by:
UCB Pharma
- License Information
